RFCA
ACHN

R&F Capital Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

R&F Capital Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$62K Buy
+14,620
New +$60.7K 0.02% 641

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

R&F Capital Advisors's ACHN Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Achillion Pharmaceuticals (ACHN) in Q1 2017: 14,620 shares worth $62K. The stake represents 0.02% of the portfolio and ranks #641 among its holdings.

130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

  • R&F Capital Advisors held 14,620 shares of Achillion Pharmaceuticals worth $62K as of Q1 2017.
  • Achillion Pharmaceuticals was a new R&F Capital Advisors position in Q1 2017.
  • Achillion Pharmaceuticals made up 0.02% of R&F Capital Advisors's portfolio in Q1 2017, its #641 holding.
  • 130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.